[Important article from Dec. 2012]
"The new DSM-5 diagnoses can be as dangerous as new drugs, but have not received the same kind of thorough risk-benefit review the U.S. Food and Drug Administration provides before approving a new medicine. And they have received no cost-benefit review.
"Having been extremely profligate in its own expenditures -- the DSM-5 has already cost $25 million, five times as much as the DSM-IV in 1994 -- the association has taken no account of the potential costs to the public from its clinically risky diagnostic changes....
"We need a broader national dialogue on mental health, its costs, and how best to spend precious resources. The DSM-5 is a giant step in the wrong direction -- away from good clinical common sense and fiscal responsibility.
"Clinicians and patients have a big stake in pushing back, and so do government and industry. The only sector that stands to benefit from the DSM-5 is the pharmaceutical business. The rest of us will pay the price."
http://www.bloomberg.com/news/2012-12-20/how-many-billions-a-year-will-the-dsm-5-cost-.html
See also:
Saving Normal: An Insider's Revolt Against Out-of-Control Psychiatric Diagnosis, DSM-5, Big Pharma, and the Medicalization of Ordinary Life by Dr. Allen Frances (2013)
Short on time? Use our Category Search page.
Comments (0)